Loading
Latest filing published 13 Sept 2022 for Talaris Therapeutics, Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Michael Zdanowski, listed as senior executive, appears in our data through filings on Talaris Therapeutics, Inc. shares, published by SEC (Form 4). Over a trading history stretching from 31 December 2021 to 10 September 2022, the count stands at 2 filings.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
The latest filing, published on 13 September 2022, reports a share grant in Talaris Therapeutics, Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations